Skip to content
Oncology Research Hub

Washington D.C., District of Columbia

Cancer clinical trials in Washington D.C., DC

158 cancer studies are recruiting participants at sites in Washington D.C. as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Washington D.C. at a glance

  • 158 studies are recruiting at a site in Washington D.C..
  • By phase: Phase 1 (13), Phase 1/2 (22), Phase 2 (37), Phase 2/3 (6), Phase 3 (53), Phase 4 (2), No phase (14), Observational (11). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (72), university, hospital or other (66), government (20).
  • By research area: Lung Cancer (48), Breast Cancer (43), Lymphoma (30), Prostate Cancer (18), Melanoma (10), Pancreatic Cancer (9).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Washington D.C.

Basic details from each study's public record (the 30 most recently updated of 158). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Georgetown Uni Hospital
    Registry record
    NCT05894239 · updated
  2. A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    MedStar Washington Hosp Center
    Registry record
    NCT07748208 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06058377 · updated
  4. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT06270706 · updated
  5. A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

    • Phase 1
    • Ages 18 to 55
    • Female participants
    Sponsor
    TerSera Therapeutics LLC
    Study site
    MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center
    Registry record
    NCT07310420 · updated
  6. A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Genentech, Inc.
    Study site
    MedStar Washington Hospital Center
    Registry record
    NCT07541079 · updated
  7. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington Hospital Center ( Site 0098)
    Registry record
    NCT06841354 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Lung cancer studies recruiting in Washington D.C.

  1. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Teligene US
    Study site
    Georgetown Lombardi Comprehensive Cancer Center
    Registry record
    NCT05168566 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT06287775 · updated
  3. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Johns Hopkins Sibley Memorial Hospital
    Registry record
    NCT07277413 · updated
  4. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Georgetown University - Lombardi Comprehensive Cancer Center
    Registry record
    NCT07111520 · updated
  5. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT04267848 · updated
  6. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Georgetown University
    Registry record
    NCT04886804 · updated
  7. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    George Washington University Medical Center
    Registry record
    NCT06096844 · updated
  8. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    OSE Immunotherapeutics
    Study site
    Georgetown Lombardi Comprehensive Cancer Center
    Registry record
    NCT06472245 · updated
  9. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Washington DC Veterans Affairs Medical Center
    Registry record
    NCT06758401 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Prostate cancer studies recruiting in Washington D.C.

  1. Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    Washington DC VA Medical Center, Washington, DC
    Registry record
    NCT04038502 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT04423211 · updated
  3. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Melanoma studies recruiting in Washington D.C.

  1. Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

    • Phase 1
    • Ages 3 to 25
    • All sexes
    Sponsor
    Children's National Research Institute
    Study site
    Children's National Hospital
    Registry record
    NCT07796061 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Lymphoma studies recruiting in Washington D.C.

  1. A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

    • No phase
    • Ages 1 to 25
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's National Medical Center
    Registry record
    NCT05621291 · updated
  2. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06724237 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Georgetown University Medical Center ( Site 0117)
    Registry record
    NCT06890884 · updated
  4. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT03739814 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT04269902 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's National Medical Center · MedStar Georgetown University Hospital
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's National Medical Center · MedStar Georgetown University Hospital
    Registry record
    NCT05675410 · updated
  8. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06337318 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Washington D.C.

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US013
    Registry record
    NCT07522073 · updated
  2. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Ask about studies near Washington D.C.

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call